Lipigon Pharmaceuticals Future Growth
Future criteria checks 2/6
Lipigon Pharmaceuticals's earnings are forecast to decline at 35% per annum while its annual revenue is expected to grow at 65.7% per year.
Key information
-35.0%
Earnings growth rate
| Biotechs earnings growth | 38.9% |
| Revenue growth rate | 65.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Feb 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
OM:LPGO - Analysts future estimates and past financials data (SEK Millions)| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|
| 12/31/2026 | 98 | N/A | N/A | 105 | 1 |
| 12/31/2025 | 27 | -25 | N/A | -26 | 1 |
| 12/31/2024 | 15 | -19 | N/A | -18 | 1 |
| 12/31/2023 | 16 | -12 | -14 | -14 | N/A |
| 9/30/2023 | 16 | -14 | -14 | -14 | N/A |
| 6/30/2023 | 16 | -16 | -28 | -28 | N/A |
| 3/31/2023 | N/A | -36 | -31 | -31 | N/A |
| 12/31/2022 | N/A | -38 | -37 | -37 | N/A |
| 9/30/2022 | 0 | -43 | -43 | -43 | N/A |
| 6/30/2022 | 1 | -48 | -47 | -47 | N/A |
| 3/31/2022 | 1 | -45 | -42 | -42 | N/A |
| 12/31/2021 | 2 | -41 | -35 | -35 | N/A |
| 9/30/2021 | 3 | -31 | -30 | -30 | N/A |
| 6/30/2021 | 4 | -21 | -19 | -18 | N/A |
| 3/31/2021 | 4 | -12 | -14 | -14 | N/A |
| 12/31/2020 | 4 | -8 | -9 | -9 | N/A |
| 12/31/2019 | 2 | -5 | -6 | -6 | N/A |
| 12/31/2018 | 0 | -4 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LPGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LPGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LPGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LPGO's revenue (65.7% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: LPGO's revenue (65.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LPGO's Return on Equity is forecast to be high in 3 years time
Discover growth companies